Healthy INSIDER Podcast 42: How FDA Commissioner Scott Gottlieb Would Affect Supplement Regs

<p style="margin: 0in 0in 8pt;">As the natural products industry attended <a href="http://www.expowest.com/ew17/Public/Enter.aspx" target="_blank">Natural Products Expo West </a>this past week, President Donald Trump stated Scott Gottlieb, M.D., is his pick for the next FDA Commissioner. Dr. Gottlieb has a history with FDA, serving as deputy commissioner for medical and scientific affairs during the George W. Bush administration. Not much is known about how Dr. Gottlieb views supplement regulations and enforcement, but his history at the agency, as a medical doctor and at the conservative think tank American Enterprise Institute gives direction on how he will lead FDA, if confirmed.&nbsp;In this podcast, Steve Mister, president and CEO of the <a href="http://www.crnusa.org/" target="_blank">Council for Responsible Nutrition</a> (CRN), and Sandy Almendarez, editor in chief of <b>Natural Products INSIDR,</b> discuss how Dr. Gottlieb may affect the supplement industry.</p>

As the natural products industry attended Natural Products Expo West this past week, President Donald Trump stated Scott Gottlieb, M.D., is his pick for the next FDA Commissioner. Dr. Gottlieb has a history with FDA, serving as deputy commissioner for medical and scientific affairs during the George W. Bush administration. Not much is known about how Dr. Gottlieb views supplement regulations and enforcement, but his history at the agency, as a medical doctor and at the conservative think tank American Enterprise Institute gives direction on how he will lead FDA, if confirmed.

In this podcast, Steve Mister, president and CEO of the Council for Responsible Nutrition (CRN), and Sandy Almendarez, editor in chief of Natural Products INSIDR, discuss how Dr. Gottlieb may affect the supplement industry, including:

  • His history at FDA, which included the establishment of GMPs (good manufacturing practices) and the passage of the Dietary Supplement and Nonprescription Drug Consumer Protection Act (adverse event reporting law)
  • What is likely to happen to the current leadership in FDA’s Office of Dietary Supplement Programs
  • The expected effect to the new dietary ingredient (NDI) draft guidance

 

Related content:

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish